ATARA BIOTHERAPEUTICS INC (ATRA) Stock Fundamental Analysis

NASDAQ:ATRA • US0465132068

4.49 USD
+0.04 (+0.9%)
At close: Feb 17, 2026
4.6999 USD
+0.21 (+4.67%)
After Hours: 2/17/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, ATRA scores 4 out of 10 in our fundamental rating. ATRA was compared to 521 industry peers in the Biotechnology industry. While ATRA is still in line with the averages on profitability rating, there are concerns on its financial health. ATRA has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year ATRA was profitable.
  • ATRA had a negative operating cash flow in the past year.
  • ATRA had negative earnings in each of the past 5 years.
  • In the past 5 years ATRA always reported negative operating cash flow.
ATRA Yearly Net Income VS EBIT VS OCF VS FCFATRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 77.57%, ATRA belongs to the top of the industry, outperforming 99.62% of the companies in the same industry.
  • ATRA's Return On Invested Capital of 271.93% is amongst the best of the industry. ATRA outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 77.57%
ROE N/A
ROIC 271.93%
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRA Yearly ROA, ROE, ROICATRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

  • Looking at the Profit Margin, with a value of 15.40%, ATRA belongs to the top of the industry, outperforming 91.94% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 27.44%, ATRA belongs to the top of the industry, outperforming 96.16% of the companies in the same industry.
  • With an excellent Gross Margin value of 81.63%, ATRA belongs to the best of the industry, outperforming 85.60% of the companies in the same industry.
Industry RankSector Rank
OM 27.44%
PM (TTM) 15.4%
GM 81.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRA Yearly Profit, Operating, Gross MarginsATRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • ATRA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for ATRA has been increased compared to 1 year ago.
  • Compared to 5 years ago, ATRA has less shares outstanding
  • Compared to 1 year ago, ATRA has a worse debt to assets ratio.
ATRA Yearly Shares OutstandingATRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATRA Yearly Total Debt VS Total AssetsATRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -83.77, we must say that ATRA is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ATRA (-83.77) is worse than 93.28% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -83.77
ROIC/WACC41.77
WACC6.51%
ATRA Yearly LT Debt VS Equity VS FCFATRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • ATRA has a Current Ratio of 1.02. This is a normal value and indicates that ATRA is financially healthy and should not expect problems in meeting its short term obligations.
  • ATRA has a Current ratio of 1.02. This is amonst the worse of the industry: ATRA underperforms 85.99% of its industry peers.
  • ATRA has a Quick Ratio of 1.02. This is a normal value and indicates that ATRA is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.02, ATRA is not doing good in the industry: 84.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
ATRA Yearly Current Assets VS Current LiabilitesATRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 108.46% over the past year.
  • ATRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 51.27%.
  • Measured over the past years, ATRA shows a very strong growth in Revenue. The Revenue has been growing by 85.07% on average per year.
EPS 1Y (TTM)108.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
Revenue 1Y (TTM)51.27%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-91.41%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.24% on average over the next years. This is quite good.
  • Based on estimates for the next years, ATRA will show a decrease in Revenue. The Revenue will decrease by -2.60% on average per year.
EPS Next Y116.48%
EPS Next 2Y41.63%
EPS Next 3Y22.84%
EPS Next 5Y17.24%
Revenue Next Year5.25%
Revenue Next 2Y-29.08%
Revenue Next 3Y-39.56%
Revenue Next 5Y-2.6%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ATRA Yearly Revenue VS EstimatesATRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20M 40M 60M 80M 100M
ATRA Yearly EPS VS EstimatesATRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 2.06, the valuation of ATRA can be described as very cheap.
  • 99.62% of the companies in the same industry are more expensive than ATRA, based on the Price/Earnings ratio.
  • ATRA is valuated cheaply when we compare the Price/Earnings ratio to 27.16, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 58.69 indicates a quite expensive valuation of ATRA.
  • Based on the Price/Forward Earnings ratio, ATRA is valued cheaply inside the industry as 89.44% of the companies are valued more expensively.
  • ATRA is valuated expensively when we compare the Price/Forward Earnings ratio to 28.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 2.06
Fwd PE 58.69
ATRA Price Earnings VS Forward Price EarningsATRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 99.42% of the companies in the same industry are more expensive than ATRA, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.16
ATRA Per share dataATRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • ATRA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ATRA's earnings are expected to grow with 22.84% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y22.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ATRA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (2/17/2026, 8:00:00 PM)

After market: 4.6999 +0.21 (+4.67%)

4.49

+0.04 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-02
Inst Owners45.78%
Inst Owner Change3.42%
Ins Owners1.66%
Ins Owner Change-0.13%
Market Cap32.37M
Revenue(TTM)151.93M
Net Income(TTM)23.40M
Analysts48.89
Price Target9.52 (112.03%)
Short Float %4.93%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.01%
Min EPS beat(2)63.52%
Max EPS beat(2)140.49%
EPS beat(4)4
Avg EPS beat(4)136.18%
Min EPS beat(4)63.52%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)49.96%
EPS beat(12)7
Avg EPS beat(12)23.63%
EPS beat(16)9
Avg EPS beat(16)20.25%
Revenue beat(2)2
Avg Revenue beat(2)138.29%
Min Revenue beat(2)134.43%
Max Revenue beat(2)142.15%
Revenue beat(4)4
Avg Revenue beat(4)485.59%
Min Revenue beat(4)67.7%
Max Revenue beat(4)1598.08%
Revenue beat(8)6
Avg Revenue beat(8)233.67%
Revenue beat(12)6
Avg Revenue beat(12)128.56%
Revenue beat(16)8
Avg Revenue beat(16)133.26%
PT rev (1m)-52.54%
PT rev (3m)-43.43%
EPS NQ rev (1m)16.03%
EPS NQ rev (3m)50.23%
EPS NY rev (1m)0%
EPS NY rev (3m)34.73%
Revenue NQ rev (1m)-15.93%
Revenue NQ rev (3m)18.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.88%
Valuation
Industry RankSector Rank
PE 2.06
Fwd PE 58.69
P/S 0.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 1.16
EPS(TTM)2.18
EY48.55%
EPS(NY)0.08
Fwd EY1.7%
FCF(TTM)-9.68
FCFYN/A
OCF(TTM)-9.67
OCFYN/A
SpS21.07
BVpS-5.08
TBVpS-5.08
PEG (NY)0.02
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 77.57%
ROE N/A
ROCE 344.22%
ROIC 271.93%
ROICexc N/A
ROICexgc N/A
OM 27.44%
PM (TTM) 15.4%
GM 81.63%
FCFM N/A
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover5.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.71
Cap/Depr 2.84%
Cap/Sales 0.06%
Interest Coverage 116.11
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z -83.77
F-Score4
WACC6.51%
ROIC/WACC41.77
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.08%
EPS Next Y116.48%
EPS Next 2Y41.63%
EPS Next 3Y22.84%
EPS Next 5Y17.24%
Revenue 1Y (TTM)51.27%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%-91.41%
Revenue Next Year5.25%
Revenue Next 2Y-29.08%
Revenue Next 3Y-39.56%
Revenue Next 5Y-2.6%
EBIT growth 1Y134.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.69%
EBIT Next 3Y17.04%
EBIT Next 5Y-3.99%
FCF growth 1Y65.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.05%
OCF growth 3YN/A
OCF growth 5YN/A

ATARA BIOTHERAPEUTICS INC / ATRA FAQ

Can you provide the ChartMill fundamental rating for ATARA BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to ATRA.


What is the valuation status of ATARA BIOTHERAPEUTICS INC (ATRA) stock?

ChartMill assigns a valuation rating of 6 / 10 to ATARA BIOTHERAPEUTICS INC (ATRA). This can be considered as Fairly Valued.


How profitable is ATARA BIOTHERAPEUTICS INC (ATRA) stock?

ATARA BIOTHERAPEUTICS INC (ATRA) has a profitability rating of 4 / 10.


What is the financial health of ATARA BIOTHERAPEUTICS INC (ATRA) stock?

The financial health rating of ATARA BIOTHERAPEUTICS INC (ATRA) is 2 / 10.


Can you provide the expected EPS growth for ATRA stock?

The Earnings per Share (EPS) of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to grow by 116.48% in the next year.